Does Synthetic Cannabis’ Cannabinoid Dronabinol Work in Dementia Care? 

As medical cannabis research grows, attention has turned to dronabinol, a synthetic form of THC approved in some countries for appetite loss and nausea. Some studies have explored whether this laboratory-made cannabinoid might also help manage agitation or behavioural symptoms in dementia, but the evidence so far remains modest and inconsistent. 

What The Research Shows 

Dronabinol acts on the same brain receptors as natural THC, producing mild psychoactive effects. Small clinical studies have examined its use in people with Alzheimer’s disease and related dementias. 

A 2019 double-blind trial published in the American Journal of Geriatric Psychiatry found that dronabinol modestly reduced agitation in Alzheimer’s patients over three weeks, but participants also experienced fatigue and occasional confusion. Similarly, a 2021 review in Frontiers in Neurology reported that cannabinoids, including dronabinol, may improve behavioural symptoms in dementia, but emphasised the low quality and small size of most studies. 

The Cochrane Database and other meta-analyses highlight that while dronabinol may slightly calm agitation or improve appetite, results vary widely, and most trials involve fewer than 50 patients. 

What The Guidelines Say 

According to NICE guidance NG144 (updated 2025), synthetic cannabinoids such as dronabinol are not recommended for dementia-related behavioural symptoms outside of clinical research. The NHS also notes that only a few cannabis-derived or synthetic products, such as Sativex and Nabilone, are licensed for specific conditions like multiple sclerosis or chemotherapy nausea, not for dementia. 

Safety And Risks 

Because dronabinol mimics THC, it can cause drowsiness, dizziness, and confusion, especially in older adults. Some participants in studies have experienced hallucinations, balance problems, and worsening memory. The Alzheimer’s Society cautions that there is no reliable evidence synthetic cannabinoids slow disease progression or improve quality of life in dementia. 

Expert Consensus 

Geriatric psychiatrists and dementia specialists from the Royal College of Psychiatrists and Mayo Clinic agree that while synthetic cannabinoids like dronabinol may show short-term calming effects, they should be used only within carefully monitored clinical trials, not as part of routine care. 

Clinical Bottom Line 

• Dronabinol is a synthetic form of THC studied for agitation and appetite loss in dementia. 

• Evidence of benefit is weak and based on small, short-term trials. 

• Sedation, confusion, and falls are common side effects. 

• NICE and NHS do not support its use outside research settings. 

• More large-scale, long-term studies are required before clinical adoption. 

About AlleviMed 

If you are exploring whether medical cannabis could be suitable for a loved one, services such as AlleviMed (launching soon) can offer eligibility consultations. These sessions help patients and families understand if cannabis-based treatments could be clinically and legally appropriate under current UK regulations. 

Takeaway 

Dronabinol may help some individuals with agitation or poor appetite, but the evidence in dementia care remains too weak for clinical use. NICE and NHS guidance recommend against prescribing synthetic cannabinoids for dementia symptoms until larger, well-controlled studies confirm safety and benefit.